These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 78079)

  • 1. 1alpha-hydroxyvitamin D.
    Brancaccio D; Galmozzi C; Casati S; Ponticelli C
    Lancet; 1978 Jun; 1(8077):1314-5. PubMed ID: 78079
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
    Teitelbaum SL
    Ann Intern Med; 1981 Mar; 94(3):404-5. PubMed ID: 6894359
    [No Abstract]   [Full Text] [Related]  

  • 3. 1,25 dihydroxyvitamin D3 and osteomalacia: some unanswered questions.
    Velentzas C; Oreopoulos DG
    Int J Artif Organs; 1980 Nov; 3(6):313-5. PubMed ID: 6893977
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparative clinical and histomorphological studies on the therapy of renal osteopathy using vitamin D and 5,6-trans-25-OHCC].
    Schulz W; Heidler R; Gessler U; Offermann G; Schulz A; Delling G
    Verh Dtsch Ges Inn Med; 1975; 81():976-80. PubMed ID: 1229631
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of renal bone disease.
    Lancet; 1979 Dec 22-29; 2(8156-8157):1339-40. PubMed ID: 92678
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications].
    García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F
    Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'One-alpha'.
    Lancet; 1978 May; 1(8071):973-4. PubMed ID: 76898
    [No Abstract]   [Full Text] [Related]  

  • 9. Proceedings: The use of metabolically-active derivatives of vitamin D in rickets and osteomalacia due to renal glomerular failure.
    Smith R; Henderson RG; Russell RG
    J Bone Joint Surg Br; 1975 May; 57(2):247-8. PubMed ID: 1141297
    [No Abstract]   [Full Text] [Related]  

  • 10. Vitamin D therapy: problems and prospects.
    Drug Ther Bull; 1975 Apr; 13(8):29-31. PubMed ID: 165927
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperparathyroidism and the predictability of response to 1alpha-hydroxyvitamin D3.
    Bone JM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():83s-84s. PubMed ID: 606429
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapeutic use of vitamin D, its derivatives and their analogs].
    Vagneur JP; Argemi B
    Diabete Metab; 1982 Mar; 8(1):65-7. PubMed ID: 6980150
    [No Abstract]   [Full Text] [Related]  

  • 13. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D therapy in uremic osteodystrophy: theoretical and practical considerations.
    Popovtzer MM
    Int J Artif Organs; 1980 Jan; 3(1):1-4. PubMed ID: 7353907
    [No Abstract]   [Full Text] [Related]  

  • 15. Osteomalacic dialysis osteodystrophy: a trial of phosphate-enriched dialysis fluid.
    Feest TG; Ward MK; Ellis HA; Aljama P; Kerr DN
    Br Med J; 1978 Jan; 1(6104):18-20. PubMed ID: 620130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis].
    Palmieri P; Albertazzi A; Cappelli P; Di Paolo B
    G Clin Med; 1981 Jul; 62(7):443-60. PubMed ID: 7308629
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis].
    Albertazzi A; Palmieri PF; Del Rosso G; Spisni C; Evangelista M
    Minerva Nefrol; 1980; 27(4):631-3. PubMed ID: 7254690
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative effect of 1alpha-hydroxycholecalciferol in children and adults with renal glomerular osteodystrophy.
    Henderson RG; Kanis JA; Ledingham JG; Oliver DO; Russel RG; Smith R; Walton RJ
    Calcif Tissue Res; 1976 Aug; 21 Suppl():221-5. PubMed ID: 782661
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral 1alpha-hydroxyvitamin D3 in the treatment of osteomalacia associated with malabsorption.
    Compston JE; Horton LW; Tighe JR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():245s-246s. PubMed ID: 606421
    [No Abstract]   [Full Text] [Related]  

  • 20. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol.
    Winterborn MH; Mace PJ; Heath DA; White RH
    Lancet; 1978 Jul; 2(8081):150-1. PubMed ID: 78344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.